{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:02:01Z","timestamp":1775134921190,"version":"3.50.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Reliable biomarkers for predicting disease progression in multiple sclerosis (MS) are crucial for advancing precision medicine and optimising treatment strategies. This study evaluates the predictive potential of serum nuclear magnetic resonance (NMR)-based metabolomics, individually and in combination with well-established biomarkers of neuroinflammation (serum glial fibrillary acidic protein, sGFAP) and axonal damage (neurofilament light chain, sNfL), in an extreme-phenotype subset of the Swiss Multiple Sclerosis Cohort (SMSC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum samples were analysed using NMR-based metabolomics, along with quantification of sNfL and sGFAP. Supervised multivariate analysis was performed to differentiate MS phenotypes and identify future progressors. Multivariable receiver operating characteristic (ROC) analysis evaluated predictive performance, with key metabolite findings validated in an independent Oxford MS cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      NMR-based metabolomics reliably distinguishes relapsing-remitting MS (RRMS) from secondary-progressive MS (SPMS) and predicts individual transitions. The identified predictive metabolites (lipoproteins, glutamine, alanine, valine, glucose) are also associated with progression independent of relapse activity (PIRA), a clinically relevant marker of sustained disability worsening. This demonstrates that the approach can both stage disease and forecast progression irrespective of stage. ROC analysis shows strong predictive performance (AUC\u2009=\u20090.81,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), with external validation confirming robustness. Integration of NMR-metabolomics with sGFAP and sNfL further improves accuracy, yielding AUCs of 0.91 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and 0.87 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0002), respectively, supported by independent validation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The integration of metabolic and protein biomarkers enables both accurate staging of RRMS versus SPMS and, critically, early prediction of progression irrespective of stage. This dual capability provides a clinically actionable, serum-based tool that can refine monitoring, improve therapeutic decision-making, and support a shift towards stage-agnostic, progression-focused care in MS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01453-5","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:36:29Z","timestamp":1772012189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum GFAP and NfL augment a metabolomics-driven strategy for long-term prediction of multiple sclerosis progression"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9477-0182","authenticated-orcid":false,"given":"Tereza","family":"Kacerova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Oechtering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Radford-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzheng","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Sealey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Saldana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Maleska Maceski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-0953","authenticated-orcid":false,"given":"Tianrong","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"DeLuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Leppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-8892","authenticated-orcid":false,"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1380-6655","authenticated-orcid":false,"given":"Daniel C.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fay","family":"Probert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"1453_CR1","doi-asserted-by":"crossref","unstructured":"Caseby, S. C. L., Woodhouse, F. A., Montgomery, S. M., Kroes, M. A. & Duddy, M. E. Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey. Health Sci. Rep. 5 (2022).","DOI":"10.1002\/hsr2.474"},{"key":"1453_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson, R. & Giovannoni, G. Multiple sclerosis - a review. Eur. J. Neurol. 26, 27\u201340 (2019).","journal-title":"Eur. J. Neurol."},{"key":"1453_CR3","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s11136-021-03034-6","volume":"31","author":"BC Healy","year":"2022","unstructured":"Healy, B. C., Zurawski, J., Chitnis, T., Weiner, H. L. & Glanz, B. I. Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. Qual. Life Res 31, 1799\u20131805 (2022).","journal-title":"Qual. Life Res"},{"key":"1453_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101861","volume":"38","author":"T Ziemssen","year":"2020","unstructured":"Ziemssen, T. et al. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: physicians\u2019 and patients\u2019 views. Mult. Scler. Relat. Disord. 38, 101861 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1453_CR5","doi-asserted-by":"publisher","first-page":"e17592","DOI":"10.2196\/17592","volume":"8","author":"C Tolley","year":"2020","unstructured":"Tolley, C. et al. A novel, integrative approach for evaluating progression in multiple sclerosis: development of a scoring algorithm. JMIR Med. Inf. 8, e17592 (2020).","journal-title":"JMIR Med. Inf."},{"key":"1453_CR6","doi-asserted-by":"crossref","unstructured":"Ziemssen, T. et al. Secondary progressive multiple sclerosis: a review of clinical characteristics, definition, prognostic tools, and disease-modifying therapies. Neurol Neuroimmunol. Neuroinflamm. 10 (2023).","DOI":"10.1212\/NXI.0000000000200064"},{"key":"1453_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley, M. P., Goldschmidt, C. H. & Rae-Grant, A. D. Diagnosis and treatment of multiple sclerosis: a review. JAMA 325, 765\u2013779 (2021).","journal-title":"JAMA"},{"key":"1453_CR8","first-page":"212","volume":"35","author":"IK Sharquie","year":"2020","unstructured":"Sharquie, I. K., Gawwam, G. A. & Abdullah, S. F. Serum glial fibrillary acidic protein: a surrogate marker of the activity of multiple sclerosis. Medeni. Med. J. 35, 212\u2013218 (2020).","journal-title":"Medeni. Med. J."},{"key":"1453_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak, A. et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat. Rev. Neurol. 18, 158\u2013172 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1453_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1177\/1352458519871818","volume":"26","author":"R Magliozzi","year":"2020","unstructured":"Magliozzi, R. & Cross, A. H. Can CSF biomarkers predict future MS disease activity and severity?. Mult. Scler. 26, 582\u2013590 (2020).","journal-title":"Mult. Scler."},{"key":"1453_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577\u2013589 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"1453_CR12","doi-asserted-by":"publisher","first-page":"108624","DOI":"10.1016\/j.intimp.2022.108624","volume":"107","author":"L Heimfarth","year":"2022","unstructured":"Heimfarth, L. et al. Serum glial fibrillary acidic protein is a body fluid biomarker: a valuable prognostic for neurological disease - A systematic review. Int. Immunopharmacol. 107, 108624 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"1453_CR13","doi-asserted-by":"publisher","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","volume":"8","author":"A Abdelhak","year":"2018","unstructured":"Abdelhak, A., Huss, A., Kassubek, J., Tumani, H. & Otto, M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci. Rep.-Uk 8, 14798 (2018).","journal-title":"Sci. Rep.-Uk"},{"key":"1453_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/1352458518819380","volume":"26","author":"H H\u00f6gel","year":"2020","unstructured":"H\u00f6gel, H. et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult. Scler. J. 26, 210\u2013219 (2020).","journal-title":"Mult. Scler. J."},{"key":"1453_CR15","doi-asserted-by":"crossref","unstructured":"Barro, C. et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 10 (2023).","DOI":"10.1212\/NXI.0000000000200052"},{"key":"1453_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier, S. et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 80, 287\u2013297 (2023).","journal-title":"JAMA Neurol."},{"key":"1453_CR17","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1093\/brain\/awae260","volume":"147","author":"E Monreal","year":"2024","unstructured":"Monreal, E. et al. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis. Brain 147, 4084\u20134093 (2024).","journal-title":"Brain"},{"key":"1453_CR18","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/acn3.52187","volume":"11","author":"E Madill","year":"2024","unstructured":"Madill, E. et al. Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis. Ann. Clin. Transl. Neurol. 11, 2719\u20132730 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1453_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.27096","volume":"97","author":"P Benkert","year":"2024","unstructured":"Benkert, P. et al. Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under B-cell depleting treatment in multiple sclerosis. Ann. Neurol. 97, 104\u2013115 (2024).","journal-title":"Ann. Neurol."},{"key":"1453_CR20","doi-asserted-by":"publisher","first-page":"104854","DOI":"10.1016\/j.msard.2023.104854","volume":"77","author":"C Ammitzb\u00f8ll","year":"2023","unstructured":"Ammitzb\u00f8ll, C. et al. NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis. Mult. Scler. Relat. Dis. 77, 104854 (2023).","journal-title":"Mult. Scler. Relat. Dis."},{"key":"1453_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert, P. et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 21, 246\u2013257 (2022).","journal-title":"Lancet Neurol."},{"key":"1453_CR22","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto, G. et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857\u2013870 (2017).","journal-title":"Ann. Neurol."},{"key":"1453_CR23","doi-asserted-by":"crossref","unstructured":"Varhaug, K. N., Torkildsen, \u00d8, Myhr, K. M. & Vedeler, C. A. Neurofilament light chain as a biomarker in multiple sclerosis. Front. Neurol. 10 (2019).","DOI":"10.3389\/fneur.2019.00338"},{"key":"1453_CR24","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jamaneurol.2019.2137","volume":"76","author":"E Cant\u00f3","year":"2019","unstructured":"Cant\u00f3, E. et al. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. Jama Neurol. 76, 1359\u20131366 (2019).","journal-title":"Jama Neurol."},{"key":"1453_CR25","doi-asserted-by":"publisher","first-page":"e2120","DOI":"10.1212\/WNL.0000000000200258","volume":"98","author":"D Leppert","year":"2022","unstructured":"Leppert, D. et al. Blood neurofilament light in progressive multiple sclerosis: post hoc analysis of 2 randomized controlled trials. Neurology 98, e2120\u2013e2131 (2022).","journal-title":"Neurology"},{"key":"1453_CR26","doi-asserted-by":"publisher","first-page":"e1898","DOI":"10.1212\/WNL.0000000000012752","volume":"97","author":"C Bridel","year":"2021","unstructured":"Bridel, C. et al. Serum neurofilament light association with progression in natalizumab-treated patients with relapsing-remitting multiple sclerosis. Neurology 97, e1898\u2013e1905 (2021).","journal-title":"Neurology"},{"key":"1453_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/13524585211032348","volume":"28","author":"J Kuhle","year":"2022","unstructured":"Kuhle, J. et al. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Mult. Scler. 28, 573\u2013582 (2022).","journal-title":"Mult. Scler."},{"key":"1453_CR28","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1212\/WNL.0000000000001491","volume":"84","author":"J Kuhle","year":"2015","unstructured":"Kuhle, J. et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 84, 1639\u20131643 (2015).","journal-title":"Neurology"},{"key":"1453_CR29","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle, J. et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92, e1007\u2013e1015 (2019).","journal-title":"Neurology"},{"key":"1453_CR30","doi-asserted-by":"publisher","first-page":"E2457","DOI":"10.1212\/WNL.0000000000009571","volume":"94","author":"A Manouchehrinia","year":"2020","unstructured":"Manouchehrinia, A. et al. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology 94, E2457\u2013E2467 (2020).","journal-title":"Neurology"},{"key":"1453_CR31","doi-asserted-by":"crossref","unstructured":"Rival, M., Galoppin, M. & Thouvenot, E. Biological markers in early multiple sclerosis: the paved way for radiologically isolated syndrome. Front Immunol. 13 (2022).","DOI":"10.3389\/fimmu.2022.866092"},{"key":"1453_CR32","doi-asserted-by":"publisher","first-page":"103535","DOI":"10.1016\/j.msard.2022.103535","volume":"59","author":"S Thebault","year":"2022","unstructured":"Thebault, S. et al. High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Mult. Scler. Relat. Dis. 59, 103535 (2022).","journal-title":"Mult. Scler. Relat. Dis."},{"key":"1453_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000422","volume":"5","author":"KN Varhaug","year":"2018","unstructured":"Varhaug, K. N. et al. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol. Neuroimmunol. Neuroinflamm. 5, e422 (2018).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1453_CR34","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1212\/WNL.0000000000000905","volume":"83","author":"AM Dickens","year":"2014","unstructured":"Dickens, A. M. et al. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology 83, 1492\u20131499 (2014).","journal-title":"Neurology"},{"key":"1453_CR35","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1177\/1352458518807076","volume":"25","author":"LM Peeters","year":"2019","unstructured":"Peeters, L. M. et al. Diagnosis and staging of multiple sclerosis using a metabolomics-based blood test: a simple method for monitoring progression independently of EDSS. Mult. Scler. J. 25, 500\u2013509 (2019).","journal-title":"Mult. Scler. J."},{"key":"1453_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69119-3","volume":"10","author":"T Yeo","year":"2020","unstructured":"Yeo, T. et al. A blood-based metabolomics test to distinguish relapsing-remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. Sci. Rep. 10, 12381 (2020).","journal-title":"Sci. Rep."},{"key":"1453_CR37","doi-asserted-by":"publisher","first-page":"7270","DOI":"10.1039\/C9AN01005J","volume":"144","author":"JA Aguilar","year":"2019","unstructured":"Aguilar, J. A. et al. Reliable, high-quality suppression of NMR signals arising from water and macromolecules: application to bio-fluid analysis. Analyst 144, 7270\u20137277 (2019).","journal-title":"Analyst"},{"key":"1453_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab240","volume":"3","author":"T Yeo","year":"2021","unstructured":"Yeo, T. et al. Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach. Brain Commun. 3, fcab240 (2021).","journal-title":"Brain Commun."},{"key":"1453_CR39","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/1352458519876020","volume":"26","author":"P Bhargava","year":"2020","unstructured":"Bhargava, P. & Anthony, D. C. Metabolomics in multiple sclerosis disease course and progression. Mult. Scler. J. 26, 591\u2013598 (2020).","journal-title":"Mult. Scler. J."},{"key":"1453_CR40","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000321","volume":"4","author":"P Villoslada","year":"2017","unstructured":"Villoslada, P. et al. Metabolomic signatures associated with disease severity in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm 4, e321 (2017).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"1453_CR41","doi-asserted-by":"crossref","unstructured":"Probert, F. et al. Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands. Front Immunol. 12 (2022).","DOI":"10.3389\/fimmu.2021.811351"},{"key":"1453_CR42","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen, C. E. et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73, 1914\u20131922 (2009).","journal-title":"Neurology"},{"key":"1453_CR43","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/ecco-jcc\/jjy101","volume":"12","author":"F Probert","year":"2018","unstructured":"Probert, F. et al. Plasma nuclear magnetic resonance metabolomics discriminates between high and low endoscopic activity and predicts progression in a prospective cohort of patients with ulcerative colitis. J. Crohns Colitis 12, 1326\u20131337 (2018).","journal-title":"J. Crohns Colitis"},{"key":"1453_CR44","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1039\/C2MB25044F","volume":"8","author":"Y Luo","year":"2012","unstructured":"Luo, Y., Zhu, J. & Gao, Y. Metabolomic analysis of the plasma of patients with high-altitude pulmonary edema (HAPE) using H NMR. Mol. Biosyst. 8, 1783\u20131788 (2012).","journal-title":"Mol. Biosyst."},{"key":"1453_CR45","doi-asserted-by":"publisher","first-page":"D622","DOI":"10.1093\/nar\/gkab1062","volume":"50","author":"DS Wishart","year":"2022","unstructured":"Wishart, D. S. et al. HMDB 5.0: the Human Metabolome Database for 2022. Nucleic Acids Res 50, D622\u2013D631 (2022).","journal-title":"Nucleic Acids Res"},{"key":"1453_CR46","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1021\/acs.jproteome.5b00354","volume":"14","author":"EA Th\u00e9venot","year":"2015","unstructured":"Th\u00e9venot, E. A., Roux, A., Xu, Y., Ezan, E. & Junot, C. Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses. J. Proteome Res. 14, 3322\u20133335 (2015).","journal-title":"J. Proteome Res."},{"key":"1453_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman, L. Random forests. Mach. Learn 45, 5\u201332 (2001).","journal-title":"Mach. Learn"},{"key":"1453_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 12, 77 (2011).","journal-title":"BMC Bioinforma."},{"key":"1453_CR49","doi-asserted-by":"publisher","first-page":"e001026","DOI":"10.1136\/bmjno-2025-001026","volume":"7","author":"DE Radford-Smith","year":"2025","unstructured":"Radford-Smith, D. E. et al. Integrating TSPO-PET imaging with metabolomics for enhanced prognostic accuracy in multiple sclerosis. BMJ Neurol. Open 7, e001026 (2025).","journal-title":"BMJ Neurol. Open"},{"key":"1453_CR50","doi-asserted-by":"publisher","first-page":"a028969","DOI":"10.1101\/cshperspect.a028969","volume":"8","author":"CC Hemond","year":"2018","unstructured":"Hemond, C. C. & Bakshi, R. Magnetic resonance imaging in multiple sclerosis. Cold Spring Harb. Perspect. Med 8, a028969 (2018).","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"1453_CR51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.addr.2020.01.004","volume":"159","author":"JFJ Bogie","year":"2020","unstructured":"Bogie, J. F. J., Haidar, M., Kooij, G. & Hendriks, J. J. A. Fatty acid metabolism in the progression and resolution of CNS disorders. Adv. Drug Deliv. Rev. 159, 198\u2013213 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1453_CR52","doi-asserted-by":"crossref","unstructured":"Pineda-Torra, I., Siddique, S., Waddington, K. E., Farrell, R. & Jury, E. C. Disrupted lipid metabolism in multiple sclerosis: a role for liver X receptors? Front Endocrinol. (Lausanne) 12, 639757 (2021).","DOI":"10.3389\/fendo.2021.639757"},{"key":"1453_CR53","doi-asserted-by":"crossref","unstructured":"Tracey, T. J., Steyn, F. J., Wolvetang, E. J. & Ngo, S. T. Neuronal lipid metabolism: multiple pathways driving functional outcomes in health and disease. Front Mol. Neurosci. 11 (2018).","DOI":"10.3389\/fnmol.2018.00010"},{"key":"1453_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35232-7","volume":"8","author":"AR Gafson","year":"2018","unstructured":"Gafson, A. R. et al. Lipoprotein markers associated with disability from multiple sclerosis. Sci. Rep. 8, 17026 (2018).","journal-title":"Sci. Rep."},{"key":"1453_CR55","doi-asserted-by":"crossref","unstructured":"Shi, J., Fan, J., Su, Q. & Yang, Z. Cytokines and abnormal glucose and lipid metabolism. Front Endocrinol (Lausanne) 10, 703 (2019).","DOI":"10.3389\/fendo.2019.00703"},{"key":"1453_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02614-8","volume":"19","author":"T Yeo","year":"2022","unstructured":"Yeo, T. et al. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model. J. Neuroinflammation 19, 252 (2022).","journal-title":"J. Neuroinflammation"},{"key":"1453_CR57","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s11011-024-01347-2","volume":"39","author":"M Sepidarkish","year":"2024","unstructured":"Sepidarkish, M., Kalantari, N., Gorgani-Firouzjaee, T., Rostami-Mansoor, S. & Shirafkan, H. Association between insulin resistance and multiple sclerosis: a systematic review and meta-analysis. Metab. Brain Dis. 39, 1015\u20131026 (2024).","journal-title":"Metab. Brain Dis."},{"key":"1453_CR58","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1021\/acschemneuro.2c00589","volume":"14","author":"E Akyuz","year":"2023","unstructured":"Akyuz, E., Celik, B. R., Aslan, F. S., Sahin, H. & Angelopoulou, E. Exploring the role of neurotransmitters in multiple sclerosis: an expanded review. ACS Chem. Neurosci. 14, 527\u2013553 (2023).","journal-title":"ACS Chem. Neurosci."},{"key":"1453_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/7191080","volume":"2020","author":"V Pegoretti","year":"2020","unstructured":"Pegoretti, V. et al. Inflammation and oxidative stress in multiple sclerosis: consequences for therapy development. Oxid. Med. Cell Longev. 2020, 1\u201319 (2020).","journal-title":"Oxid. Med. Cell Longev."},{"key":"1453_CR60","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.expneurol.2015.11.010","volume":"277","author":"K Ohl","year":"2016","unstructured":"Ohl, K., Tenbrock, K. & Kipp, M. Oxidative stress in multiple sclerosis: central and peripheral mode of action. Exp. Neurol. 277, 58\u201367 (2016).","journal-title":"Exp. Neurol."},{"key":"1453_CR61","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.toxlet.2018.05.001","volume":"298","author":"S Zakharov","year":"2018","unstructured":"Zakharov, S. et al. Neuroinflammation markers and methyl alcohol induced toxic brain damage. Toxicol. Lett. 298, 60\u201369 (2018).","journal-title":"Toxicol. Lett."},{"key":"1453_CR62","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s11064-022-03771-1","volume":"48","author":"JV Andersen","year":"2023","unstructured":"Andersen, J. V. & Schousboe, A. Glial glutamine homeostasis in health and disease. Neurochem. Res. 48, 1100\u20131128 (2023).","journal-title":"Neurochem. Res."},{"key":"1453_CR63","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","volume":"17","author":"H Kadry","year":"2020","unstructured":"Kadry, H., Noorani, B. & Cucullo, L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 17, 69 (2020).","journal-title":"Fluids Barriers CNS"},{"key":"1453_CR64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1515\/revneuro-2012-0062","volume":"24","author":"M Kostic","year":"2013","unstructured":"Kostic, M., Zivkovic, N. & Stojanovic, I. Multiple sclerosis and glutamate excitotoxicity. Rev. Neurosci. 24, 71\u201388 (2013).","journal-title":"Rev. Neurosci."},{"key":"1453_CR65","doi-asserted-by":"publisher","first-page":"103887","DOI":"10.1016\/j.mcn.2023.103887","volume":"126","author":"R Bornstein","year":"2023","unstructured":"Bornstein, R., Mulholland, M. T., Sedensky, M., Morgan, P. & Johnson, S. C. Glutamine metabolism in diseases associated with mitochondrial dysfunction. Mol. Cell Neurosci. 126, 103887 (2023).","journal-title":"Mol. Cell Neurosci."},{"key":"1453_CR66","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3233\/JPD-140389","volume":"4","author":"M Trupp","year":"2014","unstructured":"Trupp, M. et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson\u2019s disease. J. Parkinsons Dis. 4, 549\u2013560 (2014).","journal-title":"J. Parkinsons Dis."},{"key":"1453_CR67","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1039\/C5MB00711A","volume":"12","author":"A Wuolikainen","year":"2016","unstructured":"Wuolikainen, A. et al. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson\u2019s disease and control subjects. Mol. Biosyst. 12, 1287\u20131298 (2016).","journal-title":"Mol. Biosyst."},{"key":"1453_CR68","doi-asserted-by":"crossref","unstructured":"Lewerenz, J. & Maher, P. Chronic glutamate toxicity in neurodegenerative diseases-what is the evidence? Front Neurosci-Switz. 9 (2015).","DOI":"10.3389\/fnins.2015.00469"},{"key":"1453_CR69","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.neuint.2007.03.012","volume":"51","author":"AL Sheldon","year":"2007","unstructured":"Sheldon, A. L. & Robinson, M. B. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem. Int. 51, 333\u2013355 (2007).","journal-title":"Neurochem. Int."},{"key":"1453_CR70","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/metabo12040277","volume":"12","author":"N Hwangbo","year":"2022","unstructured":"Hwangbo, N. et al. Predictive modeling of Alzheimer\u2019s and Parkinson\u2019s disease using metabolomic and lipidomic profiles from cerebrospinal fluid. Metabolites 12, 277 (2022).","journal-title":"Metabolites"},{"key":"1453_CR71","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3988\/jcn.2022.18.5.529","volume":"18","author":"\u0141 Rzepi\u0144ski","year":"2022","unstructured":"Rzepi\u0144ski, \u0141, Ko\u015bli\u0144ski, P., Gackowski, M., Koba, M. & Maciejek, Z. Amino acid levels as potential biomarkers of multiple sclerosis in elderly patients: preliminary report. J. Clin. Neurol. 18, 529\u2013534 (2022).","journal-title":"J. Clin. Neurol."},{"key":"1453_CR72","doi-asserted-by":"publisher","first-page":"102512","DOI":"10.1016\/j.autrev.2020.102512","volume":"19","author":"H Inojosa","year":"2020","unstructured":"Inojosa, H., Schriefer, D. & Ziemssen, T. Clinical outcome measures in multiple sclerosis: a review. Autoimmun. Rev. 19, 102512 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1453_CR73","doi-asserted-by":"crossref","unstructured":"Letertre, M. P. M., Giraudeau, P. & de Tullio, P. Nuclear magnetic resonance spectroscopy in clinical metabolomics and personalized medicine: current challenges and perspectives. Front Mol. Biosci. 8 (2021).","DOI":"10.3389\/fmolb.2021.698337"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01453-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01453-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01453-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:02:20Z","timestamp":1775131340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01453-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01453-5","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}